Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2004 2
2005 2
2006 1
2007 3
2008 1
2009 1
2010 2
2011 4
2012 2
2013 3
2014 1
2015 2
2016 2
2018 6
2019 3
2020 5
2021 7
2022 5
2023 5
2024 1
2025 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

59 results

Results by year

Filters applied: . Clear all
Page 1
Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia.
Brown JR, Seymour JF, Jurczak W, Aw A, Wach M, Illes A, Tedeschi A, Owen C, Skarbnik A, Lysak D, Eom KS, Šimkovič M, Pavlovsky MA, Kater AP, Eichhorst B, Miller K, Munugalavadla V, Yu T, de Borja M, Ghia P; AMPLIFY investigators; AMPLIFY Investigators. Brown JR, et al. N Engl J Med. 2025 Feb 20;392(8):748-762. doi: 10.1056/NEJMoa2409804. Epub 2025 Feb 5. N Engl J Med. 2025. PMID: 39976417 Clinical Trial.
Prolymphocytic leukemia.
Absi A, Hsi E, Kalaycio M. Absi A, et al. Curr Treat Options Oncol. 2005 May;6(3):197-208. doi: 10.1007/s11864-005-0003-4. Curr Treat Options Oncol. 2005. PMID: 15869731 Review.
Comparison of a modified pediatric protocol versus a hyper-CVAD protocol in adolescents and young adults with Philadelphia-negative acute lymphoblastic leukemia: A multicenter retrospective analysis.
Salama H, Eldadah S, Omer MH, Alhejazi A, Bin Dayil L, Almozaini A, Khalil RR, Mugairi AA, Snnallah M, Damlaj M, Alaskar A, Alsaeed A, Bakkar MM, Alahmari B, Alzahrani M, Elhemaidi I, Alahmadi M, Alamoudi S, Rajkhan W, Khalil M, Kanfar SS, Saleh ASA, Raizah AA, Ibrahim A, Absi A. Salama H, et al. Among authors: absi a. Leuk Res. 2023 Jul;130:107316. doi: 10.1016/j.leukres.2023.107316. Epub 2023 May 20. Leuk Res. 2023. PMID: 37245332
Practical challenges and considerations in adopting biosimilars in oncology clinical practice within a large healthcare system.
Khan MA, Abu Esba LC, Yousef CC, Alharbi M, Modaimegh H, Metwali H, Abdulkarim H, Alshamrani M, Aseeri M, Almansour M, Alsaeed A, Alahmari M, Ansari AN, Alfoheidi M, Absi A, Alfayea T, Youssif E, Alhejazi A, Alodhaib M. Khan MA, et al. Among authors: absi a. Expert Rev Clin Pharmacol. 2025 Jun;18(6):323-331. doi: 10.1080/17512433.2025.2492063. Epub 2025 Apr 30. Expert Rev Clin Pharmacol. 2025. PMID: 40302464 Free article. Review.
Outcomes of high‑dose methotrexate for CNS prophylaxis in diffuse large B‑cell lymphoma with an intermediate or high CNS‑International Prognostic Index: A single‑center retrospective cohort study.
Al-Mansour M, Absi A, Al-Μufti R, Alahmadi M, El-Ηemaidi I, Alamoudi S, Eldadah S, Aga SS, Khan MA, Alsaeed A. Al-Mansour M, et al. Among authors: absi a. Mol Clin Oncol. 2022 Oct 13;17(6):159. doi: 10.3892/mco.2022.2592. eCollection 2022 Dec. Mol Clin Oncol. 2022. PMID: 36338604 Free PMC article.
59 results